Today's Trend
Aethlon Medical, Inc. (AEMD) — Recent analyst revisions and company disclosures are driving sentiment. The stock is trading near multi‑year weak moving averages and a very low market cap, while consensus and company results remain deeply negative (recent quarter missed estimates), which helps explain downward pressure on the share price.
- HC Wainwright raised several multi‑quarter and multi‑year EPS forecasts (FY2027–FY2030 and a series of 2027 quarterly forecasts), signaling the firm expects gradually improved results over the medium term. This could support sentiment if Aethlon executes on its plan. HC Wainwright estimate changes
- A shareholder/analyst call prepared remarks transcript was published (useful for detail on strategy, pipeline and management commentary) — may inform investors but contains no immediate market-moving announcement. Shareholder/Analyst Call Transcript
- Daily short-interest notices flagged a "large increase" in February but the reported short‑interest figure is 0 shares and days‑to‑cover shows 0.0 — the data look inconsistent/possibly erroneous, so there is no clear short‑squeeze or added short pressure indicated by these notices.
- Zacks Research lowered Q4 2026 and FY2026 EPS estimates materially (Q4 to roughly ($2.47) and FY2026 to ($10.40) in their model), reducing near‑term expectations and adding short‑term negative pressure on sentiment. Zacks estimate cuts
- Recent quarterly results showed a significant EPS miss (AEMD reported a large loss vs. consensus), and consensus full‑year estimates remain negative — these fundamentals help explain continued selling pressure and depressed valuation metrics.